AGED Diagnostics key facts
as of Oct 2026- Operator of a biotechnology company intended to create a non-invasive test for liver disease.
- AGED Diagnostics is valued at approximately $11.0M as of Oct 2026 (last reported valuation).
- It has raised $3.5M; the latest was Accelerator/Incubator in Oct 2025.
- Notable investors include Plug and Play Tech Center, TEDCO, Bioincubator, Mimosa Ventures, 757 Collab — 12 tracked in total.
- Status: Privately Held (backing).
AGED Diagnostics's last reported valuation, Feb 2025. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch AGED Diagnostics: the Monday email on marks, rounds and moves
AGED Diagnostics funding rounds
No funding rounds for AGED Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs AGED Diagnostics
12+AGED Diagnostics valuation
AGED Diagnostics's last reported valuation was $11 million in Feb 2025. No priced round, secondary trade or fund mark has surfaced since.
AGED Diagnostics investors
12 investors are on record for AGED Diagnostics, including Plug and Play Tech Center, TEDCO, Bioincubator and Mimosa Ventures.
About AGED Diagnostics
Operator of a biotechnology company intended to create a non-invasive test for liver disease. The company focuses on using transcriptional genetic analysis to identify the patterns of early tumorigenesis, enabling medical researchers to obtain an accurate depiction of their patients' health.
- Sector
- Healthcare
- HQ
- Bethesda, MD, United States
- Founded
- 2018
- Employees
- 5
- Website
- ageddiagnostics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.